Inclusion Criteria: • Pathologically proven acute myeloid leukemia (AML) or intermediate, high - risk, or very high risk Myelodysplastic Syndrome (MDS) as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS - R) which is relapsed or refractory (R / R) to standard therapy and / or for which standard therapy is contraindicated or which has not
adequately responded to standard therapy.